Comparative Pharmacology
Head-to-head clinical analysis: BACTERIOSTATIC SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTERIOSTATIC SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacteriostatic sodium chloride 0.9% is an isotonic solution used as a diluent or vehicle for medications. Sodium chloride provides osmotic balance and acts as a source of electrolytes. The bacteriostatic property is due to the presence of benzyl alcohol, which inhibits bacterial growth by disrupting bacterial cell wall synthesis and protein function.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Intravenous infusion; typical adult dose is 1000 mL every 24 hours, administered at a rate of 50-100 mL/hour, to maintain intravascular volume and correct sodium deficiency.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Approximately 30 minutes; reflects rapid renal clearance and distribution equilibrium.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Renal >99% as unchanged drug; negligible biliary or fecal elimination.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte